Treace Medical Concepts Holds Shareholder Vote

TL;DR

Treace Medical Concepts had a shareholder meeting for voting on proposals.

AI Summary

On May 21, 2024, Treace Medical Concepts, Inc. filed an 8-K report detailing a shareholder meeting where proposals were submitted for a vote. The company, incorporated in Delaware with its principal executive offices in Ponte Vedra, Florida, is involved in the surgical and medical instruments and apparatus industry.

Why It Matters

This filing indicates a formal process of shareholder engagement and decision-making, which can impact the company's governance and future strategic direction.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder meeting and does not contain information about significant financial changes or operational risks.

Key Players & Entities

• TREACE MEDICAL CONCEPTS, INC. (company) — Registrant
• May 21, 2024 (date) — Date of earliest event reported
• 100 Palmetto Park Place Ponte Vedra , Florida 32081 (address) — Principal executive offices
• 3841 (sic_code) — Standard Industrial Classification

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share TMCI The Nasdaq

Filing Documents

• tmci-20240521.htm (8-K) — 81KB
• 0000950170-24-063565.txt ( ) — 195KB
• tmci-20240521.xsd (EX-101.SCH) — 27KB
• tmci-20240521_htm.xml (XML) — 4KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. At the 2024 Annual Meeting of Stockholders (the "Meeting") of Treace Medical Concepts, Inc. (the "Company") held on May 21, 2024, the stockholders of the Company voted on the following proposals, each of which is described in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 2, 2024. The results of voting on the four proposals, including final voting tabulations, are set forth below. Proposal 1: Election of Directors. The stockholders elected, by the votes indicated below, the following nominees to the Company's Board of Directors to serve as Class III directors for a three-year term of office expiring at the 2027 annual meeting of the stockholders or until their respective successors have been duly elected and qualified: Name For Withheld Broker Non-Vote John K. Bakewell 39,111,657 9,678,827 5,994,650 Richard W. Mott 40,173,787 8,616,697 5,994,650 John T. Treace 44,023,225 4,767,259 5,994,650 Proposal 2: Advisory Vote on Executive Compensation. By the vote stated below, the stockholders approved, on an advisory, non-binding basis, the compensation of the Company's named executive officers: For Against Abstain Broker Non-Vote 44,766,561 4,009,999 13,924 5,994,650 Proposal 3: Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation By the vote stated below, the stockholders approved, on an advisory, non-binding basis, to hold future advisory votes on the compensation of the Company's named executive officers ("Say-on-Pay Votes") every 1 year: 1 Year 2 Years 3 Years Abstain Broker Non-Vote 46,655,691 118 50,989 2,083,686 5,994,650 Considering the stockholders' non-binding approval to hold future Say-on-Pay Votes every 1 year, the Company's board of directors (the "Board") has determined that future Say-on-Pay Votes will be conducted

01

Item 9.01

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TREACE MEDICAL CONCEPTS, INC. Date: May 22, 2024 By: /s/ Mark L. Hair Mark L. Hair Chief Financial Officer